21:16 , May 6, 2019 |  BC Extra  |  Company News

Lundbeck’s $250M Abide takeout lands Tourette compound, discovery hub

Lundbeck will obtain its first pipeline candidate to treat Tourette syndrome via a deal to acquire Abide. The deal will give the Danish pharma a California-based discovery site, and could also help it implement a...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
19:39 , Oct 10, 2018 |  BC Extra  |  Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
00:44 , Feb 4, 2017 |  BioCentury  |  Finance

Proteome roam

Arch Venture Partners and Versant Ventures co-led Vividion Therapeutics Inc. ’s $50 million series A round because they think the company’s platform could improve drug discovery across the board by dramatically expanding accessible targets in...
20:40 , Feb 3, 2017 |  BC Week In Review  |  Financial News

Vividion completes venture financing

Cancer, rare genetic diseases and immunology company Vividion Therapeutics Inc. (San Diego, Calif.) raised $50 million in a series A round co-led by Arch Venture Partners and Versant Ventures on Feb. 2. Existing investor Cardinal...
21:17 , Feb 2, 2017 |  BC Extra  |  Financial News

Vividion launches with $50M series A round

Vividion Therapeutics Inc. debuted on Thursday with a $50 million series A round. The company's target identification and drug development platform is designed to create candidates against proteins that have previously been considered undruggable. New...
01:34 , Apr 1, 2015 |  BC Extra  |  Financial News

aTyr raises $76M in series E

aTyr Pharma Inc. (San Diego, Calif.) raised $76 million in a series E round led by new investors Sofinnova Ventures and an undisclosed institutional investor. Other new investors included funds and accounts advised by T....
07:00 , Mar 10, 2014 |  BioCentury  |  Finance

Innovator capital rationing

Conventional wisdom says VCs don't fund research-stage companies, but the numbers - and investors who play in the space - tell a different story. Since the financial meltdown, companies with a lead program in discovery...
07:00 , Mar 10, 2014 |  BioCentury  |  Strategy

Abiding its time

Abide Therapeutics Inc. 's option deal with Celgene Corp. gives it several years to validate its serine hydrolase platform. Should Celgene opt to license ex-U.S. rights to Abide's lead inflammation programs rather than buy the...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Abide Therapeutics, Celgene deal

Celgene paid Abide $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal Partners made a $10...